Andarix Pharmaceuticals Announces Formation of Clinical Advisory Board to Advance a Targeted Lung Cancer Therapy

Share Article

A targeted and personalized medicine approach to lung cancer.

Andarix Pharmaceuticals, a clinical stage company, announces the appointment of leading clinical oncology experts to its clinical advisory board. The Advisors will work with the company to guide development of the company’s lead candidate, a novel targeted therapy for lung and other cancers. Newly appointed Advisory board members have broad expertise in clinical research and treatment of lung and neuroendocrine tumors and include: Kenneth O’Byrne, MD; Ronald Korn, MD, PhD; Martin Edelman, MD; and Michael Demeure, MD.

“We are pleased to have this distinguished group of experienced investigators join the leadership of Andarix” says Rhonda Wallen, President and Chief Operating Officer. “As we move forward with clinical development of P2045, our lead compound for lung cancer, the support and guidance of our Clinical Advisors will be invaluable, and their expertise will be an important component of our clinical development strategy.”

Dr. Michael Demeure is a member of the research faculty at the Translational Genomics Research Institute (TGEN), where he has been a Clinical Professor since 2005. Dr. Demeure attended Hahnemann University Medical School, and completed his surgical residency at the University of Arizona. He served as the president of the American Association of Endocrine Surgeons from 2008 to 2009 and has published over 80 manuscripts and book chapters. Dr. Demeure is also a member of the American College of Surgeons and the Society of Surgical Oncology. At TGEN, he serves as the Director of the Pancreatic Cancer Biospecimens Repository for a recently awarded pancreatic cancer program grant from the NIH, and directs the adrenocortical cancer center.

Dr. Martin Edelman is Professor of Medicine at the University of Maryland School of Medicine, Director of Solid Tumor Oncology, and Co-Leader of the Experimental Therapeutics Program for the University of Maryland Greenebaum Cancer Center (UMGCC). At Greenbaum, he is a member of the thoracic oncology program and currently chairs several trials in thoracic malignancies. Dr. Edelman was a member of the lung cancer and genito-urinary committees of the Southwest Oncology Group (SWOG) and has chaired two national trials in lung cancer. He is institutional Principal Investigator for the Cancer and Leukemia Group B (CALGB) at the University of Maryland and a member of the Respiratory Core Committee of the CALGB and the Lung Cancer Committee of the Radiation Therapy Oncology Group.

Dr. Ronald Korn is the medical director of Research and PET/CT at Scottsdale Medical Imaging, President of Medical Staff for Scottsdale Healthcare, and an Adjunct Professor at TGEN. Dr Korn has authored numerous articles on the role of PET in cancer and is actively involved in establishing a Center of Excellence for Neuroendocrine Cancer in Scottsdale. His research areas of interest include novel radiopharmaceuticals for cancer therapy and radiogenomics. He attended the University of Colorado at Boulder and received his PhD from the Department of Cell Biology at Albert Einstein College of Medicine in Bronx NY. He attended Stanford University Medical School and completed his Residency and Fellowship in Diagnostic Radiology and Nuclear Medicine at the University of Pennsylvania. He holds board certifications in Diagnostic Radiology and Nuclear Medicine.

Dr. Kenneth O’Byrne is a Consultant Medical Oncologist and clinical director of the HOPE directorate at St James’s Hospital, where he established the Thoracic Oncology Research Group based within the Clinical Trials Unit and the Institute of Molecular Medicine. Dr. O’Byrne is also a clinical professor at Trinity College, Dublin. He is a founding member and President of the British Thoracic Oncology Group (BTOG) and British Mesothelioma Interest Group (BMIG) and sits on the UK National Cancer Research Institute Lung Clinical Studies Group committee. He is also a co-founder and board member of the European Thoracic Oncology Platform (ETOP). He chairs the International Association for the Study of Lung Cancer (IASLC) fellowship committee and is a core member of the IASLC world conference for lung cancer (WCLC) education committee 2011. Dr. O’Byrne has a Doctorate Degree in Medicine from UCD, is a Fellow of the Royal College of Physicians, Ireland, and has published over 200 manuscripts in peer-reviewed books and journals.

About P2045
P2045 is a novel, best-in-class therapy for lung and other cancers based on a radio-labeled somatostatin peptide analogue. Early clinical studies of P2045 demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in heavily pre-treated advanced lung cancer patients. P2045 targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.

About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a clinical stage company developing targeted imaging and therapies for lung, neuroendocrine, and other cancers based on a proprietary somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Lung cancer is the leading cause of cancer mortality in the United States for both men and women. In 2009, there were an estimated 174,470 new diagnoses of non-small cell lung cancer (NSCLC) and 162,460 deaths attributable to this disease. To learn more about Andarix, please visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

C Adams
Andarix Pharmaceuticals
Email >
Visit website